Investigational Trial: Interstitial Lung Disease

This research study will evaluate an investigational agent called hymecromone to see if it can help people with interstitial lung disease or idiopathic pulmonary fibrosis (IPF). Medications that stop or reverse the progression of lung fibrosis are urgently needed. This research will determine if hymecromone can treat lung fibrosis by lowering hyaluronan levels.

Who can participate?

• Men or women with a diagnosis of interstitial lung disease.
• Not currently on supplemental oxygen, waiting for a lung transplantation, or in another treatment study for interstitial lung disease.
• Not currently diagnosed with cirrhosis, viral or non-viral hepatitis, or inflammatory bowel disease.

What is required?

• Seven visits over a five-month period.
• Taking study medication for a three-month period.
• Providing a blood sample, answering questionnaires, completing medication diary.
• Study procedures including lung function, heart, exercise, and resting tests.

What are the advantages for participants?

• The study drug may lower the levels of hyaluronan and may lessen the pulmonary fibrosis symptoms to which there is no current successful treatment.

Is compensation provided?

• Compensation is provided after each visit.

Who is running the study?

• A team, led by lung doctor, Stavros Garantziotis, M.D., at the National Institute of Environmental Health Sciences Clinical Research Unit in Research Triangle Park, North Carolina.